CD274 and endometrial cancer: A separate study, which involved only immunohistochemistry-based analysis of endometrial cancers with a PD-L1 antibody, focused on comparing samples from patients with Lynch syndrome or MLH1 promoter hypermethylation (MLH1hm) with MMR-intact patient samples [83].